Coherus BioSciences
333 Twin Dolphin Dr, #600
Redwood City
CA
94065
United States
Tel: 800-794-5434
Website: https://www.coherus.com/
About Coherus BioSciences
Coherus is focused on expanding patient access to important, cost-effective medicines and delivering significant savings to the U.S. healthcare system. Every member of the Coherus team is dedicated, motivated, and passionate about expanding patient access to lifesaving therapeutics. Our colleagues are experts in analytical and process sciences, deeply experienced in clinical development and regulatory affairs, and have proven commercial and marketing capabilities. Everyone at Coherus is committed to meeting the highest standards, inspiring our teammates, and achieving our goals.
Coherus was founded a decade ago to provide the highest quality biosimilar treatments to patients. We are proud to now be expanding our legacy—to build on our success with biosimilars and to focus our core strengths on immuno-oncology.
At Coherus, our employees are our most important asset. We have a dynamic and rewarding organizational culture that offers the opportunity to work with leading industry professionals who are dedicated to making a difference for patients. We are looking for individuals who see unlimited potential in themselves and are motivated by a continuous passion for breaking down barriers and expanding access to lifesaving therapeutics.
Coherus offers a competitive total rewards program comprised of various elements, including competitive base pay, short- and long-term incentives in the form of performance-based cash and equity, as well as health and wellness benefits that include
• Healthcare: Coherus pays 90% of premiums for medical, dental, and vision coverage for our
employees, their eligible spouses, dependents, and domestic partners.
• Health Savings and Flexible Spending Accounts
• Group Life, Disability, and Group Accident Insurance
• 401(k) with company match, and an Employee Stock Purchase Plan (ESPP)
• Paid Time Off (PTO)
• Health & Wellness programs, including a Health Club Reimbursement and an Employee Assistance Program
Health & Wellness programs, including a Health Club Reimbursement and an Employee Assistance Program
In addition to providing attractive rewards packages, we encourage and support our employees to find the right balance of work and personal time. Coherus offers a variety of activities, perks, and holidays that encourage employees to have a healthy outlook, spend time outside of work with friends and family, and foster a productive and collaborative work environment. Our culture is one in which we challenge and support all our team members to do their best work.
For more information about Coherus, please check out: https://www.coherus.com/about-coherus/
270 articles about Coherus BioSciences
-
In 2023, the FDA greenlit 55 new drugs and 34 cell and gene therapies. Follow along as BioSpace keeps you up to date on all of the FDA's decisions in 2024.
-
Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update
3/13/2024
Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today reported financial results for its fiscal fourth quarter and full year ended December 31, 2023 and recent business highlights.
-
Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024
3/5/2024
Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its fourth quarter and full year 2023 financial results will be released after market close on Wednesday, March 13, 2024.
-
Coherus BioSciences Announces New Employment Inducement Grants - February 23, 2024
2/23/2024
Coherus BioSciences, Inc., announced that effective February 20, 2024, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 170,000 shares of the common stock of the Company to three newly hired employees with a per share exercise price of $2.59, the closing trading price on the grant date.
-
Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv
2/21/2024
Coherus BioSciences, Inc. today announced the launch of UDENYCA ONBODY™, the company's on-body injector (OBI) presentation of UDENYCA ® (pegfilgrastim-cbqv).
-
Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP
2/5/2024
Coherus BioSciences, Inc. announced it has entered into an agreement with Pharmakon Advisors, LP to revise the terms of its loan agreement entered in January 2022.
-
Novartis spin-off Sandoz will make an upfront cash payment for the entire Cimerli ophthalmology franchise, including inventories, software and sales and reimbursement teams.
-
Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal
1/22/2024
Coherus BioSciences, Inc. announced it has entered into an agreement to divest its CIMERLI® ophthalmology franchise, inclusive of CIMERLI and its supporting commercial infrastructure, to Sandoz for upfront, all-cash consideration of $170 million plus an additional amount for CIMERLI product inventory and subject to customary working capital adjustments at the closing date.
-
Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium
1/18/2024
Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced data from the lead-in portion of the Phase 2 clinical trial evaluating casdozokitug (casdozo), a selective and potent IL-27-targeting antibody, in combination with atezolizumab (atezo) and bevacizumab (bev) in treatment naïve patients with unresectable locally advanced or metastatic hepatocellular carcinoma (uHCC).
-
INOVIO and Coherus Announce Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI™ (toripalimab-tpzi)
1/4/2024
INOVIO today announced a clinical collaboration and supply agreement with Coherus BioSciences, Inc. (Coherus, NASDAQ: CHRS) to evaluate the combination of INO-3112 and LOQTORZI.
-
Coherus Announces U.S. Launch of LOQTORZI™
1/2/2024
Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that LOQTORZI™ (toripalimab-tpzi) is now available through select specialty distributors in the United States.
-
Coherus Announces FDA Approval of UDENYCA ONBODY™, a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv
12/26/2023
Coherus BioSciences, Inc. announced that the U.S. Food and Drug Administration approved UDENYCA ONBODY™, the company's on-body injector presentation of UDENYCA®, a pegfilgrastim biosimilar administered the day after chemotherapy to decrease the incidence of infection as manifested by febrile neutropenia.
-
Coherus BioSciences Announces New Employment Inducement Grants - December 22, 2023
12/22/2023
Coherus BioSciences, Inc., announced that effective December 20, 2023, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 192,000 shares of the common stock of the Company to five newly hired employees with a per share exercise price of $1.94, the closing trading price on the grant date.
-
Coherus Announces Updated NCCN Clinical Practice Guidelines Positioning LOQTORZI™ (toripalimab-tpzi) as Preferred Category 1 Regimen for First-Line Treatment of Cancer of the Nasopharynx
12/11/2023
Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) announced today that the National Comprehensive Cancer Network (NCCN) has updated the clinical practice guidelines for nasopharyngeal carcinoma (NPC) to include LOQTORZI™ (toripalimab-tpzi) as a preferred, category 1 first-line treatment option for adults with metastatic or recurrent locally advanced NPC when used in combination with cisplatin and gemcitabine.
-
Coherus BioSciences Announces CFO Transition Plans
12/7/2023
Coherus BioSciences, Inc., announced that McDavid Stilwell, Chief Financial Officer, has resigned from the company to pursue other opportunities.
-
Coherus Presents Phase 1/2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2023 ESMO Immuno-Oncology Congress
12/6/2023
Coherus BioSciences, Inc., announced data from the ongoing Phase 1b/2 clinical trial of casdozokitug, a first-in-class IL-27-targeting antibody, being presented at the 2023 ESMO Immuno-Oncology Congress taking place December 6 – 8, 2023 at Palexpo Exhibition Centre in Geneva, Switzerland.
-
Coherus and Junshi Biosciences Announce Publication of Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Trial Evaluating LOQTORZI™ (toripalimab-tpzi) as Treatment for Nasopharyngeal Carcinoma, in the JAMA
11/28/2023
Coherus BioSciences, Inc. and Shanghai Junshi Biosciences Co., Ltd announced the publication of the final overall survival results from the pivotal JUPITER-02 study.
-
Coherus BioSciences Reports Third Quarter 2023 Financial Results and Business Highlights
11/6/2023
Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today reported financial results for the quarter ended September 30, 2023, and recent business highlights.
-
Coherus Presents Data from Next-generation Immuno-oncology Programs at 38th Annual Meeting of Society for Immunotherapy of Cancer (SITC)
11/3/2023
Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced data from three immuno-oncology pipeline programs at the 38th Annual Meeting of SITC taking place November 1 - 5, 2023 at the San Diego Convention Center in San Diego, CA.
-
Coherus BioSciences to Participate at Upcoming November 2023 Investor Conferences
11/3/2023
Coherus BioSciences, Inc. announced that senior management will participate in the following investor conferences.